GBD. GBD 2019 diseases and injuries. Collaborators global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–22.

Article  Google Scholar 

Drawz PE, Beddhu S, Bignall ONR, 2nd, Cohen JB, Flynn JT, Ku E, Rahman M, Thomas G, Weir MR, Whelton PK (2022) KDOQI US commentary on the 2021 KDIGO clinical practice guideline for the management of blood pressure in CKD. Am J Kidney Dis. 2022;79(3):311–327. This commentary highlights the current controversies on the topic of blood pressure targets in CKD and highlights the uniform agreement accross all hypertension societies related to accurate blood pressure measurement and out of office assessment.

United States Renal Data System. 2022 USRDS annual data report: epidemiology of kidney disease in the United States. Book 2022 USRDS annual data report: epidemiology of kidney disease in the United States.

Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LY, Sanders GD. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis. 2014;64(1):32–9.

Article  PubMed  PubMed Central  Google Scholar 

Bansal N, Szpiro A, Reynolds K, Smith DH, Magid DJ, Gurwitz JH, Masoudi F, Greenlee RT, Tabada GH, Sung SH, Dighe A, Go AS. Long-term outcomes associated with implantable cardioverter defibrillator in adults with chronic kidney disease. JAMA Intern Med. 2018;178(3):390–8.

Article  PubMed  PubMed Central  Google Scholar 

Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696–707.

Article  PubMed  Google Scholar 

Hanratty R, Chonchol M, Havranek EP, Powers JD, Dickinson LM, Ho PM, Magid DJ, Steiner JF. Relationship between blood pressure and incident chronic kidney disease in hypertensive patients. Clin J Am Soc Nephrol. 2011;6(11):2605–11.

Article  PubMed  PubMed Central  Google Scholar 

Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J, Group, S.R. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28(9):2812–23.

Article  PubMed  PubMed Central  Google Scholar 

Group SR, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT, Jr, Ambrosius WT (2021) Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 384(20):1921–1930.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. J Am Soc Hypertens. 2018;12(8):579.e571-579.e573.

Article  Google Scholar 

Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, Cutler J, Fine L, Boucher R, Wei G, Zhang C, Kramer H, Bress AP, Kimmel PL, Oparil S, Lewis CE, Rahman M, Cushman WC. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc. 2018;7(18):e009326.

Article  PubMed  PubMed Central  Google Scholar 

Dasgupta I, Zoccali C. Is the KDIGO systolic blood pressure target <120 mmHg for chronic kidney disease appropriate in routine clinical practice? Hypertension. 2022;79(1):4–11.

Article  CAS  PubMed  Google Scholar 

Drawz PE, Agarwal A, Dwyer JP, Horwitz E, Lash J, Lenoir K, McWilliams A, Oparil S, Rahbari-Oskoui F, Rahman M, Parkulo MA, Pemu P, Raj DS, Rocco M, Soman S, Thomas G, Tuot DS, Whelton PK, Pajewski NM. Concordance between blood pressure in the systolic blood pressure intervention trial and in routine clinical practice. JAMA Intern Med. 2020;180(12):1655–63.

Article  PubMed  PubMed Central  Google Scholar 

Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, Li L, Ogedegbe G, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for hypertension in adults: US preventive services task force reaffirmation recommendation statement. JAMA. 2021;325(16):1650–6.

Article  PubMed  Google Scholar 

American Diabetes Association Professional Practice, C (2022) ‘3. Prevention or delay of type 2 diabetes and associated comorbidities: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):S39–S45.

American Diabetes Association Professional Practice, C (2022) 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):S83–S96.

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: Improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–90.

Article  PubMed  PubMed Central  Google Scholar 

Kelly JT, Su G, Zhang L, Qin X, Marshall S, Gonzalez-Ortiz A, Clase CM, Campbell KL, Xu H, Carrero JJ. Modifiable lifestyle factors for primary prevention of CKD: A systematic review and meta-analysis. J Am Soc Nephrol. 2021;32(1):239–53.

Article  CAS  PubMed  Google Scholar 

Perez-Dominguez B, Casana-Granell J, Garcia-Maset R, Garcia-Testal A, Melendez-Oliva E, Segura-Orti E. Effects of exercise programs on physical function and activity levels in patients undergoing hemodialysis: a randomized controlled trial. Eur J Phys Rehabil Med. 2021;57(6):994–1001.

Article  PubMed  Google Scholar 

Sheshadri A, Kittiskulnam P, Lai JC, Johansen KL. Effect of a pedometer-based walking intervention on body composition in patients with ESRD: a randomized controlled trial. BMC Nephrol. 2020;21(1):100.

Article  PubMed  PubMed Central  Google Scholar 

Lyden K, Boucher R, Wei G, Zhou N, Christensen J, Chertow GM, Greene T, Beddhu S. Targeting sedentary behavior in CKD: A pilot and feasibility randomized controlled trial. Clin J Am Soc Nephrol. 2021;16(5):717–26.

Article  PubMed  PubMed Central  Google Scholar 

Beetham KS, Krishnasamy R, Stanton T, Sacre JW, Douglas B, Isbel NM, Coombes JS, Howden EJ. Effect of a 3-year lifestyle intervention in patients with chronic kidney disease: A randomized clinical trial. J Am Soc Nephrol. 2022;33(2):431–41.

Article  PubMed  PubMed Central  Google Scholar 

Bramlage P, Lanzinger S, Tittel SR, Hess E, Fahrner S, Heyer CHJ, Friebe M, Buschmann I, Danne T, Seufert J, Holl RW. Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations - a registry-based analysis. BMC Nephrol. 2021;22(1):184.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, Chodick G, Collins AJ, Djurdjev O, Elley CR, Evans M, Garg AX, Hallan SI, Inker LA, Ito S, Jee SH, Kovesdy CP, Kronenberg F, Heerspink HJ, Marks A, Nadkarni GN, Navaneethan SD, Nelson RG, Titze S, Sarnak MJ, Stengel B, Woodward M, Iseki K, Consortium, C.K.D.P. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA. 2016;315(2):164–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coca SG, Nadkarni GN, Huang Y, Moledina DG, Rao V, Zhang J, Ferket B, Crowley ST, Fried LF, Parikh CR. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol. 2017;28(9):2786–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, Investigators CT. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC, Committees, D.-C.T., and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

Article  CAS  PubMed  Google Scholar 

The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27.

Article  Google Scholar 

Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27–35.

Article  CAS  PubMed  Google Scholar 

Meraz-Munoz AY, Weinstein J, Wald R. eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined. Kidney360. 2021;2(6):1042–1047.

DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17(5):319–334. This is an excellent review on the role of SGLT312i in diabetic kidney disease.

Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, Group, E.S.C.S.D. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043–140.

Article  PubMed  Google Scholar 

Heerspink HJL, Cherney DZI. Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation. Clin J Am Soc Nephrol. 2021;16(8):1278–80.

Article  PubMed  PubMed Central  Google Scholar 

Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, Maldonado M, Liu CC, Liu J, Pong A, Cannon CP, Investigators VC. Ertugliflozin and slope of chronic eGFR: prespecified analyses from the randomized VERTIS CV trial. Clin J Am Soc Nephrol. 2021;16(9):1345–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Gorriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;42(48):4891–901.

Article  CAS  PubMed